View the PDF of this article at: https://www.the-jci.org/press/18589.pdf
Antibodies fend off fungal respiratory infection
Histoplasma capsulatum is the most common cause of fungal respiratory infections in the world and poses a particular threat to the elderly and immunocompromised patients such as those with HIV or organ transplant recipients undergoing immunosuppressive drug therapy. Using a mouse model of histoplasmosis, Joshua Nosanchuk and colleagues from Albert Einstein College of Medicine in New York have identified monoclonal antibodies that targeted the histone H2B-like protein of H. capsulatum and reduced fungal burden, diminished inflammation, and prolonged host survival. While vaccine development for H. capsulatum is an exciting area of research, vaccination may not be effective in immunocompromised individuals. Therefore it is conceivable that this group of individuals may benefit from passive therapy with specific monoclonal antibodies to H. capsulatum, such as those described in this report.
TITLE: Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum
AUTHOR CONTACT:
Joshua D. Nosanchuk
Albert Einstein College of Medicine, New York, New York, USA.
Phone: (718) 430-3766
Fax 1: (718) 430-8701
E-mail: nosanchu@aecom.yu.edu
View the PDF of this article at: https://www.the-jci.org/press/19361.pdf
'"/>
Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
15-Oct-2003